[Click e-Stock] "BioBisous Targets High-Value ECM Market... Corporate Value Revaluation in Focus"
Analysis suggests that BioBisous is increasingly likely to be revalued, as it has officially entered the ECM (extracellular matrix) skin booster market, which is drawing attention as a next-generation aesthetic material. After its existing HA (hyaluronic acid), PDRN, and PN-based products, the company has now added high-value-added ECM product lines, leading to expectations that it could be compared with Korea’s leading ECM companies.
Choi Jaeho, a researcher at Briars Insight, stated in a report published on July 30, 2026, “BioBisous is a company with a full product portfolio in the aesthetic market, and the market penetration of its new ECM product will be a key variable for future valuation expansion.”
Founded in 2018, BioBisous specializes in aesthetics, manufacturing and selling skin boosters, fillers, botulinum toxin products utilizing hyaluronic acid, PDRN, PN, chitosan, and more. The company is recognized for its vertically integrated structure, covering R&D, production, and sales, which ensures both cost competitiveness and quality control.
Currently, its fillers, skin boosters, and ECM products are produced in-house, while its medical cosmetics are supplied via external OEM (Original Equipment Manufacturing). As of the first quarter of this year, skin booster and ECM products accounted for 49.2% of total sales, driving performance growth. Supported by this increased product sales mix, the operating margin reached 32.4%.
The company also has a high dependence on overseas markets. Exports comprise 85.5% of total sales, with its growth base expanding around the global aesthetic market. BioBisous plans to maintain growth momentum by leading with chitosan and miPDRN/PN-based next-generation skin boosters and new ECM products.
Currently, market attention is focused on whether the company will expand its ECM skin booster business. In November last year, BioBisous signed a supply agreement with regenerative medicine company Orthotech for the ECM skin booster “Cellivion LinJ,” utilizing an acellular allogeneic dermis (hADM) based low-temperature process (Allo-PELT). In June this year, the company secured exclusive distribution rights for the product, establishing a foundation for business expansion.
In the Korean ECM market, companies such as L&C Bio and Hans Biomed have established themselves as leading players and are enjoying high corporate valuations. BioBisous aims to overcome its status as a latecomer by leveraging existing hospital and clinic distribution channels and its aesthetic product sales network.
Researcher Choi commented, “BioBisous plans to strengthen its branding and marketing to secure market competitiveness, building on established references with domestic hospitals and clinics. Although it is a latecomer, with ECM becoming a new trend in aesthetics, if it achieves greater brand recognition and a meaningful increase in market share, a revaluation of the company’s value is highly likely.”
The company set this year’s sales target for its ECM skin booster “Cellivion LinJ” at approximately KRW 5 billion. If the product successfully gains initial market traction, its contribution to performance is expected to rise rapidly.
The outlook for results is also positive. BioBisous presented a guidance of KRW 38 billion in annual sales and KRW 10 billion in operating profit for this year. This represents an increase of 33.3% in sales and 138.1% in operating profit compared to the previous year. The company aims for an operating margin of 26.3%.
Researcher Lee noted, “Even if SG&A expenses increase with the launch of new products, considering the rise in brand awareness and diversification of global sales channels, achieving KRW 10 billion in operating profit should be fully attainable. The anticipated price/earnings ratio (PER) is about 13.8 times, and depending on the outcome of its ECM market penetration, the company could be valued in line with highly rated domestic ECM firms.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, “Ultimately, the key investment point for BioBisous is the growth rate of its new ECM business. If initial market traction is confirmed, not only should performance grow, but a corporate value revaluation can be anticipated as well.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.